Abstract
Due to the potential of Indonesia as a market and a huge number of emerging new products, a comprehensive pharmacovigilance evaluation is critical in overcoming challenges and assure product safety. This article evaluates the current pharmacovigilance establishment in Indonesia in accordance with indicators stated in the manual published by WHO to identify actual challenges and solution. Evidence of compliance with each indicator was based on data published by the Indonesian national agency of drug and food control that can be accessed on the official website. Furthermore, the collected data were categorized and summarized in tables. From the table, evidence of compliance for indicators CST6, CP6-7, and CO3-8 cannot be found on any official website. These indicators are related to a system for reporting therapeutic ineffectiveness and suspected medication errors, the cost and the number of medicine-related hospital admissions and medicine-related deaths, and low human resources and report numbers. Major cause of the issues, which is reflected in the low number of annualy taken actions, is the low number of reports of Adverse Drug Reactions (ADR) which are highly dependent on the Healthcare Professionals’ (HCPs) and industries’ pharmacovigilance competency and system. Improving HCP’s competency and procurement of resources necessary to arrange the required system are considered as effective solutions for attaining a comprehensive pharmacovigilance system. Keywords: Assessment, national agency of drug and food control, pharmacovigilance, WHO Indicators
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
